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Lengthy Antimalarial Activity of Atovaquone in Human Plasma following
Atovaquone-Proguanil Administration
Recently, it was reported that sera from healthy volunteers
given atovaquone-proguanil (Malarone) inhibited parasite
transmission and asexual blood stage development for up to 6
weeks after treatment (1). The lengthy persistence of drug
activity was quite unexpected because earlier studies had
shown that proguanil and atovaquone had elimination half-
lives of about 14 to 20 h (2–4, 10, 11) and 2 to 3 days, (5, 9–11),
respectively. This drug combination acts synergistically against
malaria parasites and avoids the rapid selection of atovaquone-
resistant parasites whenever parasites are exposed to the ac-
tion of atovaquone alone (7).
The present study was designed to quantitate the persistence
of atovaquone in three Caucasian volunteers who had partic-
ipated in a study to assess the effects of repeated subclinical
infections on the development of immunity to Plasmodium
falciparum (8). The three volunteers (mean weight, 84.8 21.9
kg) had been inoculated intravenously with about 30 parasit-
ized erythrocytes of P. falciparum (3D7 strain) on three occa-
sions at 35-day intervals, and on each occasion, treatment with
atovaquone-proguanil (1,000 mg atovaquone-400 mg progua-
nil daily for 3 days) was started 8 days later. Blood samples
were collected at 6, 20, and 35 days after the onset of treatment
(Fig. 1). None of the volunteers developed symptoms of ma-
laria.
Mean plasma atovaquone concentrations-versus-time curves
measured by high-pressure liquid chromatography (HPLC) (9)
were similar after each treatment with atovaquone-proguanil
(Fig. 1). Comparable values were obtained by bioassay of sam-
ples using the 3D7 atovaquone-sensitive strain (6).
The average elimination half-life of atovaquone in the three
volunteers was 5.9 days by HPLC and 4.9 days by bioassay. The
prolonged persistence of atovaquone was further illustrated by
the complete suppression of schizont formation when plasma
collected up to 35 days after treatment was incubated with
parasites of the 3D7 strain (50% inhibitory concentration
[IC50], 2 ng/ml). In contrast, plasma collected 6 days after
treatment failed to inhibit the maturation of parasites of three
atovaquone-resistant strains (TM90-C2b, TM91-C32b, TM93-
C1088), with mean IC50 values exceeding 4,000 ng/ml (7).
These findings suggest that residual atovaquone may have con-
tributed to the suppression of malaria in the volunteers chal-
lenged with the 3D7 strain 35 days after treatment (8).
The lengthy 5- to 6-day elimination half-life of atovaquone
in these three Caucasian volunteers is twice as long as observed
previously in African and Asian patients treated with atova-
quone (5, 10, 11). Although proguanil concentrations were not
measured in this study, numerous previous studies have shown
that proguanil and its cycloguanil metabolite are eliminated
much more quickly than atovaquone (2–4, 10, 11), and none
would be present within a week after atovaquone-proguanil
treatment to potentiate the antimalarial activity of atovaquone.
The prolonged presence of atovaquone is of little concern as
long as this expensive drug continues to be used mainly by
travelers to malarious areas. However, if atovaquone-progua-
nil were used more widely by expatriate residents living in
areas of endemicity, long-lasting low atovaquone concentra-
tions in the absence of any residual proguanil may facilitate the
rapid selection of atovaquone-resistant parasites.
FIG. 1. Mean plasma atovaquone (ATQ) concentrations versus time after repeated atovaquone-proguanil treatment for uncomplicated
Plasmodium falciparum malaria in three volunteers infected on three occasions. Plasma ATQ concentrations were measured by HPLC (F) and
bioassay (E).
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